Home
Halozyme Therapeutics HALO paid Forbes-Tate $60K for lobbying in Q3 2023 · Medicare
Trade details
- Type
- Lobbying report
- Amount
- $60,000
- Quarter
- Q3 2023
- Client
- Halozyme Therapeutics
- Reported
- 23/10/17
Up 200.0% from last quarter
What else happened in Halozyme Therapeutics around then
Filed or reported within 30 days of the trade day · 23/08/31~23/10/30Halozyme Therapeutics's other lobbying reports
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$80K
$80K
Reported 07/20
for Q2
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$70K
$70K
Reported 04/18
for Q1
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 01/18
for Q4 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/10/18
for Q3 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/07/18
for Q2 2025